VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$904.35$93.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. REGN
  4. Financial Ratios

Regeneron Pharmaceuticals, Inc. (REGN) Financial Ratios

Latest Ratios: P/E Ratio 19.8x · EV/EBITDA 16.9x · ROE 14.9%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

REGN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$93.2B$83.8B$82.0B$99.9B$81.9B$70.9B$55.6B$43.0B$42.9B$43.6B$42.7B
Enterprise Value$92.8B$83.4B$82.2B$99.8B$81.5B$70.7B$56.1B$42.1B$42.1B$43.5B$42.6B
P/E Ratio →19.8218.6118.5825.2618.888.7715.8320.3417.5436.3647.67
P/S Ratio5.515.845.777.616.734.416.546.566.397.428.78
P/B Ratio3.142.682.793.843.613.785.043.884.907.099.60
P/FCF25.9720.5422.3727.2318.5110.8527.7521.5123.6642.1243.83
P/OCF18.7116.8418.5521.7416.3310.0121.2417.7119.5333.3428.73

P/E links to full P/E history page with 30-year chart

REGN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—5.825.797.616.694.406.606.426.287.408.77
EV / EBITDA16.8520.2418.3820.9314.237.6514.7217.4115.7019.5429.70
EV / EBIT25.9215.8117.0023.3716.577.5314.5117.1316.3120.6631.89
EV / FCF—20.4422.4327.2218.4210.8228.0021.0623.2442.0243.78

REGN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin85.4%85.4%86.1%82.9%86.0%83.1%84.0%85.1%91.3%90.8%91.7%
Operating Margin24.9%24.9%28.1%33.2%44.2%55.7%42.1%33.7%37.8%35.4%27.4%
Net Profit Margin31.4%31.4%31.1%30.1%35.6%50.2%41.3%32.3%36.4%20.4%18.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE14.9%14.9%16.0%16.3%20.9%54.2%31.8%21.3%32.8%22.6%22.1%
ROA11.5%11.5%12.5%12.7%15.9%37.9%22.0%15.9%23.8%15.2%14.2%
ROIC8.9%8.9%10.8%13.5%19.8%44.6%24.7%18.2%27.1%29.9%26.2%
ROCE10.2%10.2%12.6%15.6%22.6%49.7%26.3%19.2%28.3%31.1%25.3%

REGN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.090.090.090.100.120.140.240.060.080.110.11
Debt / EBITDA0.660.660.600.570.470.290.710.290.260.320.34
Net Debt / Equity—-0.010.01-0.00-0.02-0.010.05-0.08-0.09-0.02-0.01
Net Debt / EBITDA-0.10-0.100.05-0.01-0.07-0.020.13-0.37-0.28-0.05-0.04
Debt / FCF—-0.100.06-0.01-0.09-0.030.25-0.45-0.42-0.11-0.06
Interest Coverage120.42120.4287.5958.5282.80163.7567.9781.4391.5583.75185.82

Net cash position: cash ($3.1B) exceeds total debt ($2.7B)

REGN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.134.134.735.695.063.563.633.675.524.933.15
Quick Ratio3.393.393.954.944.293.072.912.994.724.292.83
Cash Ratio1.971.972.283.172.461.451.331.531.951.240.84
Asset Turnover—0.350.380.400.420.630.500.440.570.670.70
Inventory Turnover0.660.660.640.870.711.400.710.690.510.751.01
Days Sales Outstanding—146.10159.65157.70159.78137.09176.75155.05122.01122.72121.03

REGN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield0.4%0.4%—————————
Payout Ratio8.2%8.2%—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield5.0%5.4%5.4%4.0%5.3%11.4%6.3%4.9%5.7%2.8%2.1%
FCF Yield3.9%4.9%4.5%3.7%5.4%9.2%3.6%4.6%4.2%2.4%2.3%
Buyback Yield4.3%4.7%4.4%2.2%3.1%3.8%11.7%1.1%0.4%0.7%0.3%
Total Shareholder Yield4.6%5.2%4.4%2.2%3.1%3.8%11.7%1.1%0.4%0.7%0.3%
Shares Outstanding—$109M$115M$114M$114M$112M$115M$115M$115M$116M$116M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Lumpy earnings and cash timing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Trailing Multiples Look Full, Forward Discount Narrows

Based on the supplied valuation data, REGN trades at 21.77 trailing P/E and 22.47 EV/EBITDA, which compares with a 15.06 forward P/E, implying the market expects earnings to recover from the trailing base rather than extend it.

The gap between trailing and forward P/E suggests investors are pricing in sustained earnings growth, though the PEG of 3.44 indicates that growth expectations are already priced at a premium. Against peers such as VRTX at 35.41 P/E and INCY at 18.41, REGN appears moderately valued, but this comparison depends heavily on whether the recent quarterly margin expansion proves durable. Investors should monitor whether forward estimates hold given the uneven revenue history.

Margin Expansion Driven by Mix, Not Consistency

According to the reported ratio data, REGN's operating margin moved from 19.5% in 2025Q1 to 40.0% in 2026Q3, while net margin ranged from 20.2% to 40.4% across the ten quarters, showing wide quarterly dispersion.

The 2026Q3 operating margin of 40.0% sits well above the 17.8% low in 2026Q1, suggesting that high-margin revenue mix or favorable cost timing drove the latest expansion rather than a steady structural improvement. Net margin exceeding operating margin in several quarters points to non-operating contributions that warrant further investigation before treating reported earnings as recurring earning power. The trailing data alone does not establish whether the current margin level is sustainable.

Returns Oscillate Without a Clear Compounding Trend

Based on the supplied quarterly data, ROIC ranged from 1.5% in 2025Q1 to 4.8% in 2026Q3, and ROE from 2.3% to 6.0%, both remaining low relative to the 23.0% ROIC reported by VRTX and 51.1% by INCY.

Returns on invested capital remain modest for a company with a 6.5 to 8 figure equity base, which suggests that the large retained earnings and asset base are not yet generating proportional economic profit. The recent improvement in ROIC from its early-period trough is encouraging but has not yet established a sustained upward path. Compared with peers, REGN's capital efficiency appears structurally lower, though the gap may narrow if margin gains persist.

Liquidity Cushion Narrowing but Still Comfortable

As reported in financial statements, REGN's current ratio fell from 5.44 in 2024Q2 to 3.35 in 2026Q3 and quick ratio from 4.62 to 2.89, which still leaves a substantial margin above the 1.0 threshold commonly used for near-term obligations.

The steady decline in current ratio reflects growing current liabilities relative to current assets, which may indicate rising operating obligations or the deployment of cash into buybacks. Even under stress, the quick ratio near 2.9 suggests that liquid assets excluding inventory comfortably cover current liabilities. The trajectory warrants monitoring, but the absolute level does not suggest near-term liquidity strain.

Low Leverage Flatters Cash Resilience Assessment

Based on reported figures, REGN's debt-to-equity of roughly 0.08 and interest coverage above 200x in recent quarters may make the balance sheet appear stronger than the lumpy free cash flow margin, which ranged from 4.0% to 37.8%, would support.

Low leverage ratios can obscure the fact that cash generation has been erratic, and share repurchases have often absorbed most of the free cash flow produced. The most commonly misapplied metric for a biotechnology company with this profile is EV/EBITDA, since R&D spending and milestone timing can distort EBITDA materially from period to period. Investors should consider free cash flow and R&D-adjusted earnings as a more reliable gauge of earning power than the headline multiple.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open REGN Terminal

REGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

REGN — Frequently Asked Questions

Quick answers to the most common questions about buying REGN stock.

What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?

Regeneron Pharmaceuticals, Inc.'s current P/E ratio is 19.8x. The historical average is 38.4x. This places it at the 47th percentile of its historical range.

What is Regeneron Pharmaceuticals, Inc.'s EV/EBITDA?

Regeneron Pharmaceuticals, Inc.'s current EV/EBITDA is 16.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.8x.

What is Regeneron Pharmaceuticals, Inc.'s ROE?

Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) is 14.9%. The historical average is -3.0%.

Is REGN stock overvalued?

Based on historical data, Regeneron Pharmaceuticals, Inc. is trading at a P/E of 19.8x. This is at the 47th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Regeneron Pharmaceuticals, Inc.'s dividend yield?

Regeneron Pharmaceuticals, Inc.'s current dividend yield is 0.38% with a payout ratio of 8.2%.

What are Regeneron Pharmaceuticals, Inc.'s profit margins?

Regeneron Pharmaceuticals, Inc. has 85.4% gross margin and 24.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Regeneron Pharmaceuticals, Inc. have?

Regeneron Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.